Optimising sequencing of new treatments for prostate cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Karim Fizazi, MD, PhD, from Gustave Roussy, Villejuif, France, explains that recent developments in the treatment of castrate-resistant prostate cancer have improved overall survival for patients, and now, optimal sequencing of new treatment agents and approaches, such as abiraterone, enzalutamide, docetaxel, cabazitaxel, radium-223 and sipuleucel-T, is the next challenge.

Year of Production:
Running Time:


Comments are closed.